Related Experiment Video
Updated: Nov 11, 2025
07:50
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
Published on: September 18, 2020
5.8K
Methylation patterns partition pancreatic cancer into distinct prognostic subtypes
Zhiming Zhao1, Mengyang Li1, Xianglong Tan1
1Department of Hepatopancreatobiliary Surgery, The First Medical Center, Chinese People's Liberation Army General Hospital, No. 28 Fuxing Road, Haidian District, Beijing, 100853, China.
Future Oncology (London, England)
|March 31, 2021
Summary
DNA methylation is crucial in pancreatic cancer. This study identified distinct subtypes and developed a 14-site epigenetic signature to predict overall survival (OS) in pancreatic cancer patients, aiding personalized treatment.
Area of Science:
- Oncology
- Epigenetics
- Genomics
Background:
- DNA methylation is a key factor in pancreatic cancer development.
- Understanding epigenetic alterations is vital for predicting patient outcomes.
Purpose of the Study:
- To identify pancreatic cancer subtypes based on DNA methylation.
- To develop an epigenetic signature for predicting overall survival (OS).
Main Methods:
- Consensus clustering of 298 OS-related methylation sites in 147 training samples.
- Development and validation of a 14-site epigenetic signature.
- Functional enrichment analysis of methylated genes.
Main Results:
- Identified three distinct prognostic subtypes, with Cluster 1 showing poor OS.
- Developed a robust 14-methylation site signature predicting OS in training and validation cohorts.
- High- and low-risk groups based on the signature showed significant OS differences.
Conclusions:
- DNA methylation-based classification reveals pancreatic cancer heterogeneity.
- The epigenetic signature can guide prognosis prediction and personalized treatment strategies.
- This approach offers valuable clinical insights for managing pancreatic cancer.
